1-arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 320-330

  Liu, Yi Min ^a   Lee, Hsueh Yun ^a   Chen, Chun Han ^a   Lee, Chia Hua ^b   Wang, Li Ting ^b   Pan, Shiow Lin ^a   Lai, Mei Jung ^a   Yeh, Teng Kuang ^c   Liou, Jing Ping ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Histone deacetylase inhibitors; Prostate cancer; Quinoline

Indexed keywords

1 (3 METHOXYPHENYLSULFONYL) 1,2,3,4 TETRAHYDRO QUINOLINE 6 CARBALDEHYDE; 1 (3,4 DIMETHOXYPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLINE 6 CARBALDEHYDE; 1 (4 CHLOROPHENYLSULFONYL) 1,2,3,4 TETRAHYDRO QUINOLINE 6 CARBALDEHYDE; 1 (4 FLUOROPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLINE 6 CARBALDEHYDE; 1 (4 METHOXYPHENYLSULFONYL) 1,2,3,4 TETRAHYDRO QUINOLINE 6 CARBALDEHYDE; 1 (PHENYLSULFONYL) 1,2,3,4 TETRAHYDRO QUINOLINE 6 CARBALDEHYDE; 1 ARYLSULFONYL 5 (N HYDROXYACRYLAMIDE)TETRAHYDROQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXY 3 [1 [(4 METHOXYPHENYL)SULFONYL] 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]PROPANAMIDE; METHYL 1,2,3,4 TETRAHYDROQUINOLINE 6 CARBOXYLATE; METHYL QUINOLINE 6 CARBOXYLATE; N (2 AMINOPHENYL) 1 [(4 METHOXYPHENYL)SULFONYL] 1,2,3,4 TETRAHYDROQUINOLINE 6 CARBOXAMIDE; N (2 AMINOPHENYL) 3 [1 [(4 METHOXYPHENYL)SULFONYL] 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 1 [(4 METHOXYPHENYL)SULFONYL] 1,2,3,4 TETRAHYDROQUINOLINE 6 CARBOXAMIDE; N HYDROXY 3 [1 (2 BROMOPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (3 BROMOPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (3 METHOXYPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (3 NITROHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (3,4 DIMETHOXYPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (4 BROMOPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (4 CHLOROPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (4 FLUOROPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (4 METHOXYPHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (4 NITROHENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [1 (NAPHTHALENYLSULFONYL) 1,2,3,4 TETRAHYDROQUINOLIN 6 YL]ACRYLAMIDE; N HYDROXY 3 [5 (DIMETHYLAMINO)NAPHTHALENYLSULFONYL] 1,2,3,4 TETRAHYDROQUINOLIN 6 YL)ACRYLAMIDE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; HISTONE DEACETYLASE; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; UPREGULATION; WEIGHT CHANGE; ANIMAL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MALE; MICE, NUDE; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS; QUINOLONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908277134     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.052     Document Type: Article

References (28)

1. World Health Organization (WHO) http://www.who.int/.
2. National Cancer Institute http://www.cancer.gov/.
3. Cancer Research UK http://www.cancerresearchuk.org/.
4. U S Food and Drug Administration Home Page http://www.fda.gov/.
5. Prostate Cancer Foundation http://pcf.org/.
6. Y.A. Yang, J. Kim, J. Yu, Appl. Clin. Genet. 7 (2014) 81-91.
7. A. Abbas, S. Gupta, The role of histone deacetylases in prostate cancer, Epigenetics 3 (2008) 300-309.
8. M.A. Dawson, T. Kouzarides, Cancer epigenetics: from mechanism to therapy, Cell 150 (2012) 12-27.
9. M. New, H. Olzscha, N.B. La Thangue, HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol. 6 (2012) 637-656.
10. L.M. Butler, D.B. Agus, H.I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H.T. Thaler, R.A. Rifkind, P.A. Marks, V.M. Richon, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cell in vitro and in vivo, Cancer Res. 60 (2000) 5165-5170
11. P.A. Marks, Discovery and development of SAHA as an anticancer agent, Oncogene 26 (2007) 1351-1356.
12. I. Hoshino, H. Matsubara, N. Hanari, Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells, Clin. Cancer Res. 11 (2005) 7945-7952
13. N. Noureen, H. Rashid, S. Kalsoom, Identification of type-specific anticancer histone deacetylase inhibitor: road to success, Cancer Chemother. Pharmacol. 66 (2010) 625-633.
14. X. Qian, W.J. LaRochelle, G. Ara, F. Wu, K.D. Petersen, A. Thougaard, M. Sehested, H.S. Lichenstein, M. Jeffers, Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies, Mol. Cancer Ther. 5 (2006) 2086-2095
15. X. Qian, G. Ara, E. Mills, W.J. LaRochelle, H.S. Lichenstein, M. Jeffers, Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer, Int. J. Cancer 122 (2008) 1400-1410.
16. P. Atadja, Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges, Cancer Lett. 280 (2009) 233-241.
17. B.I. Lee, S.H. Park, J.W. Kim, E.A. Sausville, H.T. Kim, O. Nakanishi, J.B. Trepel, S.J. Kim, MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor β type II receptor expression in human breast cancer cells, Cancer Res. 61 (2001) 931-934.
18. A. Zubia, S. Ropero, D. Ptaegui, E. Ballestar, M.F. Fraga, M. Boix-Chornet, M. Berdasco, A. Martinez, L. Coll-Mulet, F.P. Cossío, M. Esteller, Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity, Oncogene 28 (2009) 1477-1484
19. A.T. Brunetto, J.E. Ang, R. Lal, D. Olmos, L.R. Molife, R. Kristeleit, A. Parker, I. Casamayor, M. Olaleye, A. Mais, B. Hauns, V. Strobel, B. Hentsch, J.S. de Bono, First-in-human, pharmacokinetic and pharmacodynamic phase I study of resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors, Clin. Cancer Res. 19 (2013) 5494-5504.
20. N. Masamune, O. Yoshinao, E. Takashi, A. Shin-Ichi, Y. Takashi, H. Fumihito, B. Yuji, O. Mayumi, K. Michihiko, T. Masao, T. Masazumi, Expression profile of class I histone deacetylases in human cancer tissues, Oncol. Rep. 18 (2007) 769-774
21. W. Weichert, A. Roske, T. Beckers, C. Stephan, K. Jung, F.R. Fritzsche, S. Niesporek, C. Denkert, M. Dietel, G. Kristiansen, Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectpmy, Br. J. Cancer 98 (2008) 604-610.
22. M.J. Lai, H.L. Huang, S.L. Pan, Y.M. Liu, C.Y. Peng, H.Y. Lee, T.K. Yeh, P.H. Huang, C.M. Teng, C.S. Chen, H.Y. Chuang, J.P. Liou, Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo, J. Med. Chem. 55 (2012) 3777-3791
23. C.H. Chen, M.C. Chen, J.C. Wang, A.C. Tsai, C.S. Chen, J.P. Liou, S.L. Pan, C.M. Teng, Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo, Clin. Cancer Res. 20 (2014) 1274-1287
24. M.C. Chen, C.H. Chen, J.C. Wang, A.C. Tsai, J.P. Liou, S.L. Pan, C.M. Teng, The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFRTKI-resistant NSCLC cells, Cell Death Dis. 4 (2013) e810
25. H.Y. Lee, C.R. Yang, M.J. Lai, H.L. Huang, Y.L. Hsieh, Y.M. Liu, T.K. Yeh, Y.H. Li, S. Mehndiratta, C.M. Teng, J.P. Liou, 1-Arylsulfonyl-5-(N-hydroxyacrylamide) indolines histone deacetylase inhibitors are potent cytokine release suppressors, Chem BioChem 14 (2013) 1248-1254
26. H.Y. Lee, A.C. Tsai, M.C. Chen, P.J. Shen, Y.C. Cheng, C.C. Kuo, S.L. Pan, Y.M. Liu, J.F. Liu, T.K. Yeh, J.C. Wang, C.Y. Chang, J.Y. Chang, J.P. Liou, Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells, J. Med. Chem. 57 (2014) 4009-4022.
27. Y.S. Cho, L. Jiang, M. Shultz, Heterocycle Compounds and Methods of Thereof. Assignee: Norvartis AG. US 20100022514 A1.
28. T.A. Gaweco, W. Jefferson, W. John, P. Samantha, B. James, ROR Modulators and Their Uses. WO 2013166013 A1.